Multimodal SPION-CREKA peptide based agents for molecular imaging of microthrombus in a rat myocardial ischemia-reperfusion model

Biomaterials

Volumn 35, Issue 9, 2014, Pages 2961-2970

  Song, Yanan ^a   Huang, Zheyong ^a   Xu, Jianfeng ^a   Ren, Daoyuan ^a   Wang, Yu ^a   Zheng, Xinde ^a   Shen, Yunli ^b   Wang, Lili ^a   Gao, Hongxiang ^a   Hou, Jiayun ^a   Pang, Zhiqing ^a   Qian, Juying ^a   Ge, Junbo ^a  

^a FUDAN UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

Author keywords

APTT; CREKA; FFP; Fibrin; Magnetic resonance imaging; MI R; Microthrombosis; MRI; Multimodal nanoagents; Optical imaging; PEG; PT; SPION; TT

Indexed keywords

FIBRIN; MAGNETIC RESONANCE IMAGING; MICROTHROMBOSIS; MULTIMODAL NANOAGENTS; OPTICAL IMAGING;

ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; DEXTRANS; DISEASE MODELS, ANIMAL; HUMANS; MAGNETITE NANOPARTICLES; MALE; MICROSCOPY, FLUORESCENCE; MOLECULAR IMAGING; MULTIMODAL IMAGING; MYOCARDIAL REPERFUSION INJURY; NANOPARTICLES; OLIGOPEPTIDES; OPTICAL IMAGING; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; STATIC ELECTRICITY; THROMBOSIS;

EID: 84895002003     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.12.038     Document Type: Article

References (42)

1. Zhang Z.G., Chopp M., Goussev A., Lu D., Morris D., Tsang W., et al. Cerebral microvascular obstruction by fibrin is associated with upregulation of PAI-1 acutely after onset of focal embolic ischemia in rats. J Neurosci 1999, 19:10898-10907.
2. Geiser T., Sturzenegger M., Genewein U., Haeberli A., Beer J.H. Mechanisms of cerebrovascular events as assessed by procoagulant activity, cerebral microemboli, and platelet microparticles in patients with prosthetic heart valves. Stroke 1998, 29:1770-1777.
3. Heye N., Cervos-Navarro J. Microthromboemboli in acute infarcts: analysis of 40 autopsy cases. Stroke 1996, 27:431-434.
4. Ojio S., Takatsu H., Tanaka T., Ueno K., Yokoya K., Matsubara T., et al. Considerable time from the onset of plaque rupture and/or thrombi until the onset of acute myocardial infarction in humans: coronary angiographic findings within 1 week before the onset of infarction. Circulation 2000, 102:2063-2069.
5. Virmani R., Forman M.B., Kolodgie F.D. Myocardial reperfusion injury. Histopathological effects of perfluorochemical. Circulation 1990, 81:IV57-IV68.
6. Bekkers S.C., Yazdani S.K., Virmani R., Waltenberger J. Microvascular obstruction: underlying pathophysiology and clinical diagnosis. J Am Coll Cardiol 2010, 55:1649-1660.
7. Shao L., Wu D., Zhang P., Li W., Wang J., Su G., et al. The significance of microthrombosis and fgl2 in no-reflow phenomenon of rats with acute myocardial ischemia/reperfusion. Clin Appl Thromb Hemost 2013, 19:19-28.
8. Galasso G., Schiekofer S., D'Anna C., Di Gioia G., Piccolo R., Niglio T., et al. No-reflow phenomenon: pathophysiology, diagnosis, prevention, and treatment. A review of the current literature and future perspectives. Angiology 2013, http;//dx.doi.org/10.1177/0003319712474336. Available from URL: http://www.ncbi.nlm.nih.gov/pubmed/23362304.
9. Camici P.G., Crea F. Coronary microvascular dysfunction. N Engl J Med 2007, 356:830-840.
10. Kothawade K., Bairey Merz C.N. Microvascular coronary dysfunction in women: pathophysiology, diagnosis, and management. Curr Probl Cardiol 2011, 36:291-318.
11. Shimizu A., Hisashi Y., Kuwaki K., Tseng Y.L., Dor F.J., Houser S.L., et al. Thrombotic microangiopathy associated with humoral rejection of cardiac xenografts from alpha1,3-galactosyltransferase gene-knockout pigs in baboons. Am J Pathol 2008, 172:1471-1481.
12. Flacke S., Fischer S., Scott M.J., Fuhrhop R.J., Allen J.S., McLean M., et al. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 2001, 104:1280-1285.
13. Yu X., Song S.K., Chen J., Scott M.J., Fuhrhop R.J., Hall C.S., et al. High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn Reson Med 2000, 44:867-872.
14. Hilderbrand S.A., Weissleder R. Near-infrared fluorescence: application to in vivo molecular imaging. Curr Opin Chem Biol 2010, 14:71-79.
15. Flaumenhaft R., Tanaka E., Graham G.J., De Grand A.M., Laurence R.G., Hoshino K., et al. Localization and quantification of platelet-rich thrombi in large blood vessels with near-infrared fluorescence imaging. Circulation 2007, 115:84-93.
16. Sim D.S., Merrill-Skoloff G., Furie B.C., Furie B., Flaumenhaft R. Initial accumulation of platelets during arterial thrombus formation in vivo is inhibited by elevation of basal cAMP levels. Blood 2004, 103:2127-2134.
17. Lanza G.M., Wallace K.D., Scott M.J., Cacheris W.P., Abendschein D.R., Christy D.H., et al. A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation 1996, 94:3334-3340.
18. Simberg D., Duza T., Park J.H., Essler M., Pilch J., Zhang L., et al. Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci U S A 2007, 104:932-936.
19. Brigger I., Chaminade P., Desmaele D., Peracchia M.T., d'Angelo J., Gurny R., et al. Near infrared with principal component analysis as a novel analytical approach for nanoparticle technology. Pharm Res 2000, 17:1124-1132.
20. Huang Z., Shen Y., Pei N., Sun A., Xu J., Song Y., et al. The effect of nonuniform magnetic targeting of intracoronary-delivering mesenchymal stem cells on coronary embolisation. Biomaterials 2013, 34:9905-9916.
21. Massberg S., Enders G., Leiderer R., Eisenmenger S., Vestweber D., Krombach F., et al. Platelet-endothelial cell interactions during ischemia/reperfusion: the role of P-selectin. Blood 1998, 92:507-515.
22. Jung C.W., Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 1995, 13:661-674.
23. Jung C.W. Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 1995, 13:675-691.
24. Weissleder R., Stark D.D., Engelstad B.L., Bacon B.R., Compton C.C., White D.L., et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol 1989, 152:167-173.
25. Keselowsky B.G., Collard D.M., Garcia A.J. Surface chemistry modulates focal adhesion composition and signaling through changes in integrin binding. Biomaterials 2004, 25:5947-5954.
26. Mahmoudi M., Sant S., Wang B., Laurent S., Sen T. Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev 2011, 63:24-46.
27. Massberg S., Enders G., Matos F.C., Tomic L.I., Leiderer R., Eisenmenger S., et al. Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. Blood 1999, 94:3829-3838.
28. Peters D., Kastantin M., Kotamraju V.R., Karmali P.P., Gujraty K., Tirrell M., et al. Targeting atherosclerosis by using modular, multifunctional micelles. Proc Natl Acad Sci U S A 2009, 106:9815-9819.
29. Hong S., Leroueil P.R., Majoros I.J., Orr B.G., Baker J.R., Banaszak Holl M.M. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol 2007, 14:107-115.
30. Li M.H., Choi S.K., Thomas T.P., Desai A., Lee K.H., Kotlyar A., et al. Dendrimer-based multivalent methotrexates as dual acting nanoconjugates for cancer cell targeting. Eur J Med Chem 2012, 47:560-572.
31. Sirol M., Fuster V., Badimon J.J., Fallon J.T., Moreno P.R., Toussaint J.F., et al. Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation 2005, 112:1594-1600.
32. Sirol M., Aguinaldo J.G., Graham P.B., Weisskoff R., Lauffer R., Mizsei G., et al. Fibrin-targeted contrast agent for improvement of in vivo acute thrombus detection with magnetic resonance imaging. Atherosclerosis 2005, 182:79-85.
33. Overoye-Chan K., Koerner S., Looby R.J., Kolodziej A.F., Zech S.G., Deng Q., et al. EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus. J Am Chem Soc 2008, 130:6025-6039.
34. von zur Muhlen C., von Elverfeldt D., Moeller J.A., Choudhury R.P., Paul D., Hagemeyer C.E., et al. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation 2008, 118:258-267.
35. Miserus R.J., Herias M.V., Prinzen L., Lobbes M.B., Van Suylen R.J., Dirksen A., et al. Molecular MRI of early thrombus formation using a bimodal alpha2-antiplasmin-based contrast agent. JACC Cardiovasc Imaging 2009, 2:987-996.
36. Uppal R., Ay I., Dai G., Kim Y.R., Sorensen A.G., Caravan P. Molecular MRI of intracranial thrombus in a rat ischemic stroke model. Stroke 2010, 41:1271-1277.
37. Tassa C., Shaw S.Y., Weissleder R. Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc Chem Res 2011, 44:842-852.
38. Wang Y.X., Hussain S.M., Krestin G.P. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 2001, 11:2319-2331.
39. Asanuma T., Ono M., Kubota K., Hirose A., Hayashi Y., Saibara T., et al. Super paramagnetic iron oxide MRI shows defective Kupffer cell uptake function in non-alcoholic fatty liver disease. Gut 2010, 59:258-266.
40. Harisinghani M.G., Barentsz J., Hahn P.F., Deserno W.M., Tabatabaei S., van de Kaa C.H., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003, 348:2491-2499.
41. Boccaccio C., Sabatino G., Medico E., Girolami F., Follenzi A., Reato G., et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005, 434:396-400.
42. Zhang Y., Fan S., Yao Y., Ding J., Wang Y., Zhao Z., et al. In vivo near-infrared imaging of fibrin deposition in thromboembolic stroke in mice. PLoS One 2012, 7:e30262.